Stock Events

Stock Events

Jade Biosciences 

$14.39
56
+$0.24+1.7% 20:00 Today
-$0.18-1.25%21:04After hours

Statistics

Day High
14.81
Day Low
14
52W High
28
52W Low
8.36
Volume
735,510
Avg. Volume
904,606
Mkt Cap
915.17M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 16Expected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-12.1
-8.21
-4.32
-0.43
Expected EPS
-0.733922
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-127.41MNet Income

Analyst Ratings

$50.60Average Price Target
The highest estimate is ⁦74.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JBIO. It's not an investment recommendation.
NVIDIA
5
NVDA
Johnson & Johnson
3
JNJ
AGNC Investment
3
AGNC
Oxford Lane Capital
3
OXLC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is a competitor because it develops and markets therapies for treating cystic fibrosis, a space where Aerovate Therapeutics is also aiming to innovate with its cardiovascular and pulmonary disease treatments.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is involved in the research and development of drugs for pulmonary diseases among other areas, making it a direct competitor to Aerovate Therapeutics in the pulmonary treatment market.
Arvinas
ARVN
Mkt Cap484.51M
Arvinas, Inc. is focused on developing therapies for cancers and other difficult-to-treat diseases, including lung diseases, which puts it in competition with Aerovate Therapeutics.
Incyte
INCY
Mkt Cap23.37B
Incyte Corporation works on the discovery, development, and commercialization of proprietary therapeutics, including for serious pulmonary conditions, competing with Aerovate Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical Inc. focuses on enzyme replacement therapies and other drug developments for rare genetic diseases, some of which involve pulmonary aspects, competing with Aerovate.
Sarepta Therapeutics
SRPT
Mkt Cap1.85B
Sarepta Therapeutics, Inc. is known for its focus on RNA-targeted therapeutics, including treatments for rare diseases, some of which may overlap with Aerovate Therapeutics' focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals, Inc. works on RNAi therapeutics for the treatment of rare diseases, including those affecting the lungs, making it a competitor to Aerovate Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for the treatment of serious medical conditions, including pulmonary diseases, competing with Aerovate Therapeutics.

About

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Show More
CEO
Tom Frohlich
Employees
55
Country
United States
ISIN
US0080642061

Listings

XNAS
US
JBIO
BOATS
BOATS
JBIO.BOATS

0 Comments

Share your thoughts

FAQs

What is Jade Biosciences stock price today?▼
The current price of JBIO is $14.39 USD — it has increased by +1.7% in the past 24 hours. Watch Jade Biosciences stock price performance more closely on the chart.
What is Jade Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Jade Biosciences stocks are traded under the ticker JBIO.
Is Jade Biosciences stock price growing?▼
JBIO stock has risen by +1.91% compared to the previous week, the month change is a -24.5% fall, over the last year Jade Biosciences has showed a +53.09% increase.
What is Jade Biosciences market cap?▼
Today Jade Biosciences has the market capitalization of 915.17M
When is the next Jade Biosciences earnings date?▼
Jade Biosciences is going to release the next earnings report on November 16, 2026.
What were Jade Biosciences earnings last quarter?▼
JBIO earnings for the last quarter are -0.76 USD per share, whereas the estimation was -0.64 USD resulting in a -19.42% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Jade Biosciences revenue for the last year?▼
Jade Biosciences revenue for the last year amounts to 0 USD.
What is Jade Biosciences net income for the last year?▼
JBIO net income for the last year is -127.41M USD.
How many employees does Jade Biosciences have?▼
As of October 9, 2026, the company has 55 employees.
In which sector is Jade Biosciences located?▼
Jade Biosciences operates in the Health & Wellness sector.
When did Jade Biosciences complete a stock split?▼
The last stock split for Jade Biosciences was on April 29, 2025 with a ratio of 1:35.
Where is Jade Biosciences headquartered?▼
Jade Biosciences is headquartered in WALTHAM, United States.